Overview

A simple mobile app allows patients to detect retinal diseases

This product is available on cobas® pulse system.

AlleyeOne is aimed at healthcare providers who want to offer their customers smart screening for retinal diseases. AlleyeOne detects diseases of the retina presenting with metamorphopsia. Diseases include age-related macular degeneration (AMD) and diabetic macular edema (DME).

Early detection and treatment prevent from irreversible vision loss. Therefore, it is important that your customers use AlleyeOne to detect these diseases early. We recommend using the AlleyeOne test twice a year for risk groups (patients with diabetes and people 50+).

AlleyeOne

Smart screening for retinal diseases

Benefits

Simple. Secure. Reliable eye test.

The AlleyeOne app is designed for the detection and characterization of central and paracentral metamorphopsia (visual distortions) in at risk population.

Patients can play a simple game to detect retinal diseases. While being fun to use, AlleyeOne is also CE marked and received FDA 510(k) clearance.

Early detection of retinal diseases

With a simple eye test, AlleyeOne assesses a patient’s capability to see straight lines as straight. The test task consists of placing the middle of three dots on an invisible connecting line of the two outer dots.

The Alleye test is up to ten times more accurate than a conventional eye test. The benefits of Alleye have been demonstrated in several clinical studies.

Real-time feedback on visual performance

The patients receive an Alleye score right after the test. This gives them feedback on their visual performance. If the score falls below a certain threshold, AlleyeOne recommends visiting an eye doctor for further examination.

Oculocare medical is committed to build digital innovations that save people from blindness and vision impairment. The Swiss digital health company was founded in 2015 and is a subsidiary of medignition. Oculocare works at the intersection of ophthalmology, statistics, design, and technology. We develop scientific digital products to promote eye health. The company's flagship product is Alleye, which enables people to detect retinal disease and functional deterioration via a mobile app.

Visit website
Disclaimer
  • Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.